In Reply - 03/06/21
Doi : 10.1016/j.jaac.2021.04.007
Le texte complet de cet article est disponible en PDF.
| All statements expressed in this column are those of the authors and do not reflect the opinions of the Journal of the American Academy of Child and Adolescent Psychiatry. See the Guide for Authors for information about the preparation and submission of Letters to the Editor. The authors have reported no funding for this work. |
|
| Members of AACAP's Psychopharmacology Committee are: Christoph U. Correll, MD, of Hofstra/Northwell, Mina K. Dulcan, MD, of Ann and Robert H. Lurie Children's Hospital of Chicago, Graham J. Emslie, MD, of the University of Texas Southwestern Medical Center, Tiffany R. Farchione, MD, of the US Food and Drug Administration, Robert L. Findling, MD, MBA, of Virginia Commonwealth University, Boris Lorberg, MD, of the University of Massachusetts Medical School, Theodore A. Petti, MD, MPH, of Rutgers University, Adelaide S. Robb, MD (co-chair), of Children's National Health System, Takuya Saito, MD, PhD, of Nippon Medical School, John T. Walkup, MD, of Ann and Robert H. Lurie Children's Hospital of Chicago, and Timothy Wilens, MD (co-chair), of Massachusetts General Hospital. Paul E. Croarkin, DO, of the Mayo Clinic, is a member of the committee but has recused himself from signing the reply as he was co-author of the letter to the editor and an author of the Mayo study. Disclosure: Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, IntraCellular Therapies, Janssen/JandJ, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Janssen and Otsuka. He has served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. Dr. Croarkin has received research funding from the Brain and Behavior Research Foundation, the Mayo Clinic Foundation, the National Institute of Mental Health (NIMH), Pfizer, Inc., Neuronetics, Inc., and NeoSync, Inc. He has received equipment support for investigator-initiated studies from Neuronetics, Inc. and MayVenture, Inc. He has received supplies and genotyping services from Assurex Health for an investigator-initiated study. He has served as a paid consultant for Procter and Gamble Company, Myriad Neuroscience, and Sunovion. Dr. Dulcan has reported receiving book royalties from American Psychiatric Association Publishing. Dr. Emslie has received research support from Duke University, Forest Research Institute (partner of Merck KgaA; formerly known as Forest Laboratories), and Janssen Pharmaceuticals, Research and Development. He has been a consultant for Lundbeck, Neuronetics, and Otsuka. Dr. Findling has received research support, acted as a consultant, and/or has received honoraria from Acadia, Adamas, Afecta, Akili, Alkermes, Allergan, the American Academy of Child and Adolescent Psychiatry (AACAP), American Psychiatric Press, Arbor, Axsome, Emelex, Gedeon Richter, Genentech, Idorsia, Intra-Cellular Therapies, Luminopia, Lundbeck, MedAvante-ProPhase, MJH Life Sciences, the National Institutes of Health (NIH), Neurim, Otsuka, PaxMedica, Pfizer, Q BioMed, Receptor Life Sciences, Roche, Sage, Signant Health, Sunovion, Supernus Pharmaceuticals, Syneos, Syneurx, Takeda, Teva, and Tris in the past 24 months. Dr. Robb has received research support, acted as a consultant, and/or has received honoraria, had IRA stock holdings in from Actavis/ Allergan/Forest, AACAP, the American Academy of Pediatrics (AAP), Eli Lilly and Co., Glaxo Smith Kline, I-ACT, Johnson and Johnson, Lundbeck/Takeda, Neuroscience Educational Institute, the National Center for Advancing Translational Sciences, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIMH, the National Center for CME, Otsuka, Pfizer, and Supernus in the past 24 months. Dr. Saito has received grants from Shionogi and Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. and received personal fees from Shionogi and Co., Ltd., Takeda Pharmaceutical Company Limited, Sumitomo Dainippon Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and Otsuka Pharmaceutical Co., Ltd. Dr. Walkup has reported receiving royalties from the following sources: Guilford Press, Oxford University Press, and Wolters Kluwer. He has served on the advisory boards of the following organizations: The Anxiety Disorders Association of America, the Tourette Association, and the Trichotillomania Learning Center. He has received honoraria from AAP. Dr. Wilens is Chief, Division of Child and Adolescent Psychiatry and (Co) Director of the Center for Addiction Medicine at Massachusetts General Hospital. He has received grant support from the following sources: NIH (the National Institute on Drug Abuse). He has published a book, Straight Talk About Psychiatric Medications for Kids (Guilford Press) and co/edited books: ADHD in Adults and Children (Cambridge University Press). He is co/owner of a copyrighted diagnostic questionnaire (Before School Functioning Questionnaire) and has a licensing agreement with Ironshore (BSFQ Questionnaire). He has been a consultant for Arbor Pharmaceuticals, Otsuka, Vallon, and Ironshore, and has served as a clinical consultant to the US National Football League (ERM Associates), US Minor/Major League Baseball, the Gavin Foundation, and Bay Cove Human Services. Drs. Lorberg and Petti have reported no biomedical financial interests or potential conflicts of interest. |
© 2019
Publié par Elsevier Masson SAS.
Vol 60 - N° 6
P. 664-666 - juin 2021 Retour au numéro
Article précédent
- Thoughtful Clinical Use of Pharmacogenetics in Child and Adolescent Psychopharmacology
- Laura B. Ramsey, Lisa B. Namerow, Jeffrey R. Bishop, J. Kevin Hicks, Chad Bousman, Paul E. Croarkin, Carol A. Mathews, Sara L. Van Driest, Jeffrey R. Strawn
- Attachments: The Pediatric Symptom Checklist: A Bridge to Child and Adolescent Psychiatry From Pediatrics
- Michael S. Jellinek
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?